Peroxisome Proliferator Activated Receptor
Peroxisome Proliferator Activated Receptor - Related Videos
05:57
Peroxisome Staining in Mammalian Cells Using Peroxisome-Specific Probes
0 Views •
2025
PeroxiSPY probes are used to detect peroxisomes in mammalian cells. Here we demonstrate how to use the probes to stain peroxisomes in live and fixed cells.
12:02
High-throughput Analysis of Mammalian Olfactory Receptors: Measurement of Receptor Activation via Luciferase Activity
0 Views •
Cited by 16 •
2014
Olfactory receptor activation patterns encode odor identity, but the lack of published data identifying odorant ligands for mammalian olfactory receptors hinders the development of a comprehensive model of odor coding. This protocol describes a method to facilitate high-throughput identification of olfactory receptor ligands and quantification of receptor activation.
09:04
Detection of Neu1 Sialidase Activity in Regulating TOLL-like Receptor Activation
0 Views •
Cited by 39 •
2010
The sialidase assay is a simple technical approach that will elucidate novel molecular mechanism(s) of TLR sensors of microbial infections and involvement in inflammatory diseases at the receptor level on the cell surface of live macrophages.
03:52
Estrogen Receptor-Reporter Activity Assay to Screen Phytoestrogen Estrogenic Activity
0 Views •
2025
This video describes a cell-based reporter assay to determine the estrogenic activity of plant-derived compounds. A compound with estrogen-like activity mimics its binding to estrogen receptors and drives downstream reporter enzyme gene transcription. The reporter enzyme generates bioluminescence in a reaction, indicating the estrogenic activity of the compound.
11:45
Quantifying Agonist Activity at G Protein-coupled Receptors
0 Views •
Cited by 10 •
2011
A method for estimating the affinity constant of an agonist for the active state (Kb) of a G protein-coupled receptor is described. The analysis provides absolute or relative measures of Kb depending on whether constitutive receptor activation is measurable. Our method applies to various responses downstream from receptor activation.
FAQs
Ligand binding initiates a transcriptional sequence in which a PPAR pairs with retinoid X receptor and engages a peroxisome proliferator response element in DNA. The complex then recruits cofactors that modify transcription of target genes. This mechanism explains how fatty acids and therapeutic ligands can produce pharmacological effects through changes in gene expression rather than through rapid signaling alone.
The three PPAR subtypes differ in tissue distribution and biological function, so activating one subtype does not necessarily reproduce the effects of activating another. These differences help explain why PPAR-directed drugs can influence distinct aspects of lipid metabolism, glucose homeostasis, inflammation, or cellular differentiation. Subtype biology therefore provides an important basis for designing and evaluating targeted therapies.
Cofactors determine how the DNA-bound PPAR and retinoid X receptor complex alters transcription. Their recruitment provides a regulatory step between receptor activation and changes in target-gene expression. This step is pharmacologically important because ligand binding alone does not describe the complete response; the resulting transcriptional regulation helps connect receptor engagement with metabolic, inflammatory, or differentiation-related outcomes.
Fibrates and thiazolidinediones illustrate how pharmacological ligands can exploit PPAR signaling for different therapeutic purposes. Fibrates are associated with treatment of dyslipidemia, whereas thiazolidinediones are used in type 2 diabetes. Their differing clinical roles reflect the distinct functions and distributions of PPAR subtypes, rather than a single uniform effect produced by all PPAR activation.
Subtype specificity matters because PPARα, PPARγ, and PPARδ have distinct distributions and functions, which can shape both desired effects and safety considerations. A ligand that favors one subtype may be investigated to focus treatment on a particular metabolic or inflammatory outcome. Consequently, pharmacological research continues to examine subtype-specific effects instead of treating PPAR activation as one interchangeable process.
PPAR-directed research addresses dyslipidemia, type 2 diabetes, metabolic regulation, inflammation, and cellular differentiation. Existing drugs demonstrate therapeutic value, but subtype-specific effects and safety considerations remain important limitations. Pharmacologists therefore study how different ligands engage the receptor system and how those interactions may support improved approaches to metabolic and inflammatory disease.